Organisation paid for research Program year 2025 Source: CMS Open Payments

Conquest Research LLC

Neither a doctor nor a teaching hospital

Research payments

$36,220,971

652 payments

Through program year 2025, Conquest Research LLC is reported as receiving $36,220,971 in research payments, across 652 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$15,011,225	117
2024	Research	$5,751,405	157
2023	Research	$4,219,682	80
2022	Research	$4,112,224	85
2021	Research	$4,395,567	110
2020	Research	$1,162,540	43
2019	Research	$1,568,329	60

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $15,804,200 92 payments
Amgen Inc. $7,927,526 7 payments
Regeneron Pharmaceuticals, Inc. $2,981,000 118 payments
AbbVie, Inc. $2,534,623 99 payments
Seikagaku Corporation $2,491,165 55 payments
Janssen Research & Development, LLC $774,099 46 payments
Endo Pharmaceuticals Inc. $754,175 41 payments
Novartis Pharmaceuticals Corporation $691,994 1 payment
Genentech, Inc. $514,040 14 payments
Sage Therapeutics, Inc. $486,797 13 payments

Studies the money was for Research payments · program years 2019–2025

A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants $6,269,179 1 payment
A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $2,642,423 96 payments
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $2,616,454 6 payments
6603/1133 $2,491,165 55 payments
A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,435,248 4 payments
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $1,327,500 2 payments
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM $1,194,140 1 payment
A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,189,258 2 payments
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $1,177,471 4 payments
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease $1,106,874 18 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $146,377 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.